These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12919333)

  • 1. Issues in clinical trial design from the FDA perspective.
    Katz R
    Epilepsia; 2003; 44 Suppl 7():9-15. PubMed ID: 12919333
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary. Reflections in a crystal ball.
    Lasagna L
    Clin Pharmacol Ther; 1975 Jul; 18(1):1-8. PubMed ID: 1097147
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 5. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nurses and clinical trials.
    Snyder SL
    J Cardiovasc Nurs; 1994 Jan; 8(2):86-90. PubMed ID: 8182419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA perspective on clinical trial design for femoropopliteal stent correction of peripheral vascular insufficiency cardiovascular devices.
    Goode J; Sapirstein W; Zuckerman B
    Catheter Cardiovasc Interv; 2007 May; 69(6):920-1. PubMed ID: 17455345
    [No Abstract]   [Full Text] [Related]  

  • 8. Women in clinical trials: an FDA perspective.
    Sherman LA; Temple R; Merkatz RB
    Science; 1995 Aug; 269(5225):793-5. PubMed ID: 7638593
    [No Abstract]   [Full Text] [Related]  

  • 9. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group.
    Williams RL; Patnaik RN; Chen ML
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of one-sided tests in drug trials: an FDA advisory committee member's perspective.
    Fisher LD
    J Biopharm Stat; 1991; 1(1):151-6. PubMed ID: 1844686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA issues requirement for retaining drug samples.
    Oncology (Williston Park); 1991 May; 5(5):176. PubMed ID: 1832001
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of an FDA guidance document for clinical trials in SLE.
    Siegel JN
    Lupus; 1999; 8(8):581-5. PubMed ID: 10568893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to use FDA drug approval documents for evidence syntheses.
    Ladanie A; Ewald H; Kasenda B; Hemkens LG
    BMJ; 2018 Jul; 362():k2815. PubMed ID: 29991565
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer Center Launched Within FDA.
    Voelker R
    JAMA; 2017 Mar; 317(9):900. PubMed ID: 28267838
    [No Abstract]   [Full Text] [Related]  

  • 15. MSC-based product characterization for clinical trials: an FDA perspective.
    Mendicino M; Bailey AM; Wonnacott K; Puri RK; Bauer SR
    Cell Stem Cell; 2014 Feb; 14(2):141-5. PubMed ID: 24506881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The placebo control in clinical trials (a view from the FDA).
    Leber P
    Psychopharmacol Bull; 1986; 22(1):30-2. PubMed ID: 3726077
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials.
    Faris O; Shuren J
    N Engl J Med; 2017 Apr; 376(14):1350-1357. PubMed ID: 28379790
    [No Abstract]   [Full Text] [Related]  

  • 19. Current issues in clinical trial design: superiority versus equivalency studies.
    Landow L
    Anesthesiology; 2000 Jun; 92(6):1814-20. PubMed ID: 10839934
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.